CMS sets $8.32 DefenCath add‑on for Q1 2027; CorMedix reaffirms 2026 revenue guidance and reports $355 M cash
CorMedix Therapeutics announced it holds about $355 million in cash as of September 30, 2026 and kept its full‑year 2026 revenue outlook at $325 million‑$345 million. The Centers for Medicare & Medicaid Services released a final rule on October 28, 2026 establishing an $8.32 add‑on payment per DefenCath dialysis session for the first quarter of 2027, within the company’s previously guided range. CorMedix expects the add‑on to fall in Q2 2027 before rising again in Q3 and Q4, with the average rate for the year projected to be more than twice the current $2.37 level. The company will discuss its third‑quarter results on November 12, 2026.
Why it matters
The higher Medicare add‑on could boost CorMedix’s reimbursement revenue in 2027, while the unchanged 2026 guidance signals no immediate earnings impact. Investors will watch the November 12 earnings call for details on how the new payment rate translates into sales and cash flow.
Key facts
- 1Unaudited cash and cash equivalents were approximately $355 million as of September 30, 2026. stocktitan.net
- 2Full‑year 2026 total revenue guidance remains between $325 million and $345 million. stocktitan.net
- 3CMS set a post‑TDAPA add‑on payment of $8.32 per DefenCath dialysis session for Q1 2027. stocktitan.net
- 4The current add‑on rate for the third and fourth quarters of 2026 is $2.37 per session. stocktitan.net
- 5CorMedix anticipates the DefenCath add‑on will decline in Q2 2027 compared with Q1, then increase in Q3 and/or Q4. stocktitan.net
- 6The company expects the average add‑on rate for all four quarters of 2027 to exceed twice the current $2.37 rate, i.e., more than $4.74 per session. finance.yahoo.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.